# A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients

> **NCT07303660** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Lomond Therapeutics Holdings, Inc.** · enrollment: 66 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** ZE50-0134
- **DRUG:** Azacitidine Days 1-7
- **DRUG:** ZE 50-0134

## Key facts

- **NCT ID:** NCT07303660
- **Lead sponsor:** Lomond Therapeutics Holdings, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-10
- **Primary completion:** 2026-09
- **Final completion:** 2027-11
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07303660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07303660, "A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07303660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*